https://www.eventscribe.net/2021/ASAM/SearchByExpoCompany.asp
Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients ALA-1000 is the first, three-month slow-release Buprenorphine injection. Initial results show a low initial burst without dose dumping effect, good safety, and tolerability. ALA-1000 has the potential to significantly increase compliance and reduce the risk of relapse in patients treated and stabilized with oral medications or other, shorter-interval Buprenorphine LAIs.…
Alar Pharmaceuticals Inc., a new drug development company focused on long-acting release drug products, has announced that it concluded its pre-Investigational New Drug (pre-IND) meeting with U.S. Food and Drug Administration (FDA) for ALA-3000 on August 21, 2020. ALA-3000 is a developing long-acting new drug to treat patients with treatment-resistant depression (TRD), which is designed with specific features to have safety benefits. In the written response, US FDA agrees with…
